Advertisement

Differentiated Thyroid Cancer and Pulmonary Metastasis

  • Çiğdem Soydal
  • Elgin Özkan
Chapter

Abstract

A 50-year-old female patient exhibiting hyperthyroidism, with no known risk factors for thyroid cancer, underwent thyroid ultrasound. Multiple thyroid nodules with different echo patterns were detected. A fine needle aspiration biopsy (FNAB) detected a papillary thyroid carcinoma in the cold nodule in the left lobe. The intraoperative evaluation determined that the central compartment lymph nodes were enlarged, so the patient underwent a total thyroidectomy and a bilateral central compartment lymph node dissection. Histopathological examination of the surgical specimen revealed two foci of papillary thyroid carcinomas, 3 and 0.7 cm in size, in both thyroid lobes with extra-thyroidal soft tissue invasion and lymph node metastases (T2N1aMx, ATA intermediate risk group). A 5550 MBq (150 mCi) I-131 dose was administered under endogenous TSH elevation. After 6 months of radioiodine treatment (RAT), diagnostic whole-body scintigraphy was performed with 185 MBq (5 mCi) I-131. Although, there was no pathological uptake at the thyroid bed or any site during whole-body scintigraphy, stimulated Tg serum levels were 140 ng/ml. No pathologic lesion was detected in the neck ultrasound. For this reason, the patient underwent 18F-FDG PET/CT. Multiple 18F-FDG avid lung nodules were identified with a SUVmax of 2.7. Diagnostic computed tomography of the thorax revealed multiple millimetric metastatic nodules in both lungs.

Keywords

Papillary thyroid carcinoma Lung metastases Tyrosine kinase inhibitors 

References

  1. 1.
    Vassilopoulou-Sellin R. Management of papillary thyroid cancer. Oncology (Williston Park). 1995;9:145–51.Google Scholar
  2. 2.
    Samaan NA, Schultz PN, Hickey RC, Goepfert H, Haynie TP, Johnston DA, et al. The results of various modalities of treatment of well differentiated thyroid cancer: a retrospective review of 1599 patients. J Clin Endocrinol Metab. 1992;75:714–20.  https://doi.org/10.1210/jcem.75.3.1517360.CrossRefPubMedGoogle Scholar
  3. 3.
    Mazzaferri EL. Papillary thyroid carcinoma: factors influencing prognosis and current therapy. Semin Oncol. 1987;14:315–32.PubMedGoogle Scholar
  4. 4.
    Ruegemer JJ, Hay ID, Bergstralh EJ, Ryan JJ, Offord KP, Gorman CA. Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables. J Clin Endocrinol Metab. 1988;67:501–8.CrossRefGoogle Scholar
  5. 5.
    Robbins J, Merino MJ, Boice JD Jr, Ron E, Ain KB, Alexander HR, et al. Thyroid cancer: a lethal endocrine neoplasm. Ann Intern Med. 1991;115:133–47.CrossRefGoogle Scholar
  6. 6.
    Massin JP, Savoie JC. Pulmonary metastases in differentiated thyroid carcinoma. Cancer. 1984;53:982–92.CrossRefGoogle Scholar
  7. 7.
    Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomized, double-blind, phase 3 trial. Lancet. 2013;384:319–28.  https://doi.org/10.1016/S0140-6736(14)60421-9.CrossRefGoogle Scholar
  8. 8.
    Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372:621–30.  https://doi.org/10.1056/NEJMoa1406470.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Haugen BR, Alexander EK, Bible KC, Doherty G, Mandel SJ, Nikiforov YE, et al. American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133.  https://doi.org/10.1002/cncr.30360.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Schlumberger M, Brose M, Elisei R, Leboulleux S, Luster M, Pitoia F, et al. NCCN clinical practice guidelines in oncology, thyroid carcinoma, 2015 version 2, (2015). NCCN.org definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol. 2014;2:356–8.  https://doi.org/10.1016/S2213-8587(13)70215-8.CrossRefPubMedGoogle Scholar
  11. 11.
    Ito Y, Suzuki S, Ito K, Imai T, Okamoto T, Kitano H, et al. Tyrosine-kinase inhibitors to treat radioiodine-refracted, metastatic, or recurred and progressive differentiated thyroid carcinoma. Endocr J. 2016;30(63):597–602.  https://doi.org/10.1507/endocrj.EJ16-0064.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  • Çiğdem Soydal
    • 1
  • Elgin Özkan
    • 2
  1. 1.Department of Nuclear MedicineAnkara University School of MedicineAnkaraTurkey
  2. 2.Department of Nuclear MedicineMedical Faculty of Ankara UniversityAnkaraTurkey

Personalised recommendations